ArticleBMB reports2018
Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy.
Article in BMB reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Mesenchymal Stromal Cell-derived Extracellular Vesicles in Preclinical Animal Models of Tumor Growth: Systematic Review and Meta-analysis.Stem cell reviews and reports · 2022Pooled it
- Nanoparticle-Mediated Transcytosis in Tumor Drug Delivery: Mechanisms, Categories, and Novel Applications.Current drug delivery · 2026Review
- Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies.Medicine · 2025Review
- Microcargos with Megaeffects: A Literature Review of Immunomodulatory, Diagnostic, Prognostic, and Therapeutic Dimensions of Exosomal MicroRNAs in Glioblastoma Multiforme.Cellular and molecular neurobiology · 2025Review
- MSC-derived extracellular vesicles: Precision miRNA delivery for overcoming cancer therapy resistance.Regenerative therapy · 2025Review
- Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.Regenerative therapy · 2025Review
- Natural and Bioengineered Extracellular Vesicles in Diagnosis, Monitoring and Treatment of Cancer.ACS nano · 2025Review
- The Mechanism of Action of Exosomes Derived from Glioblastoma Cells.Current medicinal chemistry · 2025Review
- Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment.Frontiers in oncology · 2025Review
- The Masquelet technique triggers the formation of a network involving LncRNA, circRNA, miRNA, and mRNA during bone repair.Annals of medicine · 2024Article
- Exploring the clinical implications and applications of exosomal miRNAs in gliomas: a comprehensive study.Cancer cell international · 2024Review
- Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment.Biomedicines · 2024Review
- miRNA-Driven Regulation of Endothelial-to-Mesenchymal Transition Differs among Thoracic Aortic Aneurysms.Cells · 2024Article
- Mesenchymal Stem Cell-Derived Extracellular Vesicles in Cancer Therapy Resistance: from Biology to Clinical Opportunity.International journal of biological sciences · 2024Review
- Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy.Molecular neurobiology · 2023Review
- An update in the applications of exosomes in cancer theranostics: from research to clinical trials.Journal of cancer research and clinical oncology · 2023Review
- Exosomes as Novel Diagnostic Biomarkers and Therapeutic Tools in Gliomas.International journal of molecular sciences · 2023Review
- Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer.Pharmaceutics · 2023Review
- Recent Advancements on the Use of Exosomes as Drug Carriers for the Treatment of Glioblastoma.Life (Basel, Switzerland) · 2023Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are small membranous vesicles which contain abundant RNA molecules, and are transferred from releasing cells to uptaking cells. MicroRNA (miRNA) is one of the transferred molecules affecting the adopted cells, including glioma cells. We hypothesized that mesenchymal stem cells (MSCs) can secrete exosomes loading miRNA and have important effects on the progress of gliomas. To determine these effects by treating exosomal miRNA in culture media of miRNA mimic transfected MSCs, we assessed the in vitro cell proliferation and invasion capabilities, and the expression level of relative proteins associated with cell apoptosis, growth and migration. For animal studies, the mice injected with U87 cells were exposed to exosomes derived from miRNA-584-5p transfected MSCs, to confirm the influence of exosomal miRNA on the progress of glioma. Based on our results, we propose a new targeted cancer therapy wherein exosomes derived from miRNA transfected MSCs could be used to modulate tumor progress as the anticancer vehicles. [BMB Reports 2018; 51(8): 406-411].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.